ADC Therapeutics SA logo

ADCT - ADC Therapeutics SA Share Price

$32.19 0.4  1.4%

Last Trade - 5:54pm

Sector
Healthcare
Size
Mid Cap
Market Cap £1.77bn
Enterprise Value £1.44bn
Revenue £n/a
Position in Universe 1943rd / 6626
Bullish
Bearish
Unlock ADCT Revenue
Momentum
Relative Strength (%)
1m -15.5%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -43.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 1.80 1.14 2.34 0.77 35.1 +13.9%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, ADCTherapeutics SA revenues was not reported. Net loss totaledto $190.4M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ADCT Revenue Unlock ADCT Revenue

Net Income

ADCT Net Income Unlock ADCT Revenue

Normalised EPS

ADCT Normalised EPS Unlock ADCT Revenue

PE Ratio Range

ADCT PE Ratio Range Unlock ADCT Revenue

Dividend Yield Range

ADCT Dividend Yield Range Unlock ADCT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ADCT EPS Forecasts Unlock ADCT Revenue
Profile Summary

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 6, 2011
Public Since October 3, 2019
No. of Shareholders: n/a
No. of Employees: 179
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange New York Stock Exchange
Shares in Issue 76,718,648
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADCT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADCT
Upcoming Events for ADCT
Frequently Asked Questions for ADC Therapeutics SA
What is the ADC Therapeutics SA share price?

As of 5:54pm, shares in ADC Therapeutics SA are trading at $32.19, giving the company a market capitalisation of £1.77bn. This share price information is delayed by 15 minutes.

How has the ADC Therapeutics SA share price performed this year?

Shares in ADC Therapeutics SA are currently trading at $32.19 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ADC Therapeutics SA price has moved by % over the past year.

What are the analyst and broker recommendations for ADC Therapeutics SA?

There are no analysts currently covering ADC Therapeutics SA.

When will ADC Therapeutics SA next release its financial results?

ADC Therapeutics SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the ADC Therapeutics SA dividend yield?

ADC Therapeutics SA does not currently pay a dividend.

Does ADC Therapeutics SA pay a dividend?

ADC Therapeutics SA does not currently pay a dividend.

When does ADC Therapeutics SA next pay dividends?

ADC Therapeutics SA does not currently pay a dividend.

How do I buy ADC Therapeutics SA shares?

To buy shares in ADC Therapeutics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ADC Therapeutics SA?

Shares in ADC Therapeutics SA are currently trading at $32.19, giving the company a market capitalisation of £1.77bn.

Where are ADC Therapeutics SA shares listed? Where are ADC Therapeutics SA shares listed?

Here are the trading details for ADC Therapeutics SA:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: ADCT
What kind of share is ADC Therapeutics SA?

Based on an overall assessment of its quality, value and momentum, ADC Therapeutics SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a ADC Therapeutics SA share price forecast 2021?

Shares in ADC Therapeutics SA are currently priced at $32.19. At that level they are trading at 56.44% discount to the analyst consensus target price of 0.00.

Analysts covering ADC Therapeutics SA currently have a consensus Earnings Per Share (EPS) forecast of -3.525 for the next financial year.

How can I tell whether the ADC Therapeutics SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ADC Therapeutics SA. Over the past six months, the relative strength of its shares against the market has been -45.11%. At the current price of $32.19, shares in ADC Therapeutics SA are trading at -15.43% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ADC Therapeutics SA PE Ratio?

We were not able to find PE ratio data for ADC Therapeutics SA.

Who are the key directors of ADC Therapeutics SA?

ADC Therapeutics SA's management team is headed by:

Peter Corr - DRC
Stephane Henchoz - FID
Chris Martin - CEO
Michael Forer - VCH
Patrick Van Berkel - SVP
Peter Hug - DRC
Jennifer Herron - OTH
Ron Squarer - CHM
Who are the major shareholders of ADC Therapeutics SA?

Here are the top five shareholders of ADC Therapeutics SA based on the size of their shareholding:

Auven Therapeutics General LP Corporation
Percentage owned: 28.93% (22.2m shares)
HPWH TH AG Corporation
Percentage owned: 9.71% (7.45m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 9.4% (7.21m shares)
Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 8.28% (6.35m shares)
AstraZeneca (UK) Ltd. Corporation
Percentage owned: 5.23% (4.01m shares)
Similar to ADCT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.